Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25467832 | 1.00 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL24530643 | 1.00 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL24372870 | 0.98 | GNAO1 (0.42) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL20224766 | 0.92 | GBA1 (0.41) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL24356351 | 0.85 | GNAO1 (0.61) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL19604919 | 0.85 | GNAO1 (0.61) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL25467830 | 0.84 | HRH3 (0.39) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL10052289 | 0.84 | ARG1 (0.38) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL20224764 | 0.83 | GBA1 (0.40) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL19602184 | 0.83 | SIGMAR1 (0.57) | GNAO1GNAI3GNAI1SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | GNAO1 2247/4885GNAI3 3323/4885GNAI1 2846/4885 |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | GNAO1 67/4885GNAI3 82/4885GNAI1 17/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | GNAO1 1650/4885GNAI3 1393/4885GNAI1 1205/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | GNAO1 1650/4885GNAI3 1393/4885GNAI1 1205/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | GNAO1 1794/4885GNAI3 1017/4885GNAI1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.